Draig Therapeutics’ lead drug is designed to safely target the AMPA receptor as a way of mediating the interplay between two neurotransmitters whose imbalance is associated with mood disorders. The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or entering clinical testing.
The post Draig Therapeutics Emerges With $140M for Clinical Tests of Novel Neuropsychiatric Drugs appeared first on MedCity News.
